Results 161 to 170 of about 136,710 (292)

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol‐free and low‐alcohol products in higher risk groups

Addiction, EarlyView.
Abstract Alcohol‐free and low‐alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high‐income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol‐related health problems should take a zero‐tolerance approach to these alcohol‐like products or encourage patients to ...
John Holmes, Christopher K. Oldroyd, Colin Drummond, Matt Field, Inge Kersbergen, Michael E. D. Allison   +5 more
wiley   +1 more source

Parent PTSD, social support and differential associations with facets of anxiety sensitivity. [PDF]

Eur J Psychotraumatol
Bermingham K, Latourrette C, Chartier KG, Spit for Science Working Group, Amstadter AB, Bountress K.   +5 more
europepmc   +1 more source

Alcohol Problems. ABC of Alcohol. Alcohol and Alcoholism [PDF]

Postgraduate Medical Journal, 1983
openaire   +1 more source

Risk of cancers of the lung, head and neck in patients hospitalized for alcoholism in Sweden [PDF]

, 2001
Paolo Boffetta, Weimin Ye, H‐O Adami, Lorelei A. Mucci, Olof Nyrén   +4 more
openalex   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Short-Term Alcohol Consumption Is Sufficient to Disrupt Microbial Communities and the Intestinal and Circulating Metabolites in a Non-Human Primate Model. [PDF]

FASEB J
Blanton MB, Napier EG, Keen KE, Stuart EV, Cinco IR, Hemati H, Bruntz RC, Khadka R, Grant KA, Messaoudi I.   +9 more
europepmc   +1 more source

Alcoholism: from neurobiology to new treatment approaches

, 2009
Jerzy Samochowiec
openalex   +1 more source

Analysis of genes for alcoholism using two-disease-locus models [PDF]

, 2005
Chih‐Chieh Wu, Sanjay Shete
openalex   +1 more source

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

Age- and alcohol-related differences in adolescent neurometabolite levels. [PDF]

Alcohol Clin Exp Res (Hoboken)
Perica MI, Kirkland AE, Mewton L, Squeglia LM.   +3 more
europepmc   +1 more source